✳flâneur — a map of the web's best reading

Association for Molecular Pathology v. Myriad Genetics, Inc. - Wikipedia

en.wikipedia.org · 6,486 words · saved by 1 readers

Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013), was a Supreme Court case, which decided that "a naturally occurring DNA segment is a product of nature and not patent eligible merely because it has been isolated."[1] However, the Court allowed patenting of complementary DNA, which contains exactly the same protein-coding base pair sequence as the natural DNA, albeit with introns removed.[2] The lawsuit in question challenged the validity of gene patents in the United States, specifically questioning certain claims in issued patents owned or controlled by Myriad Genetics that cover isolated DNA sequences, methods to diagnose propensity to cancer by looking for mutated DNA sequences, and methods to identify drugs using isolated DNA sequences.[3] Prior to the case, the U.S. Patent Office accepted patents on isolated DNA sequences as a composition of matter. Diagnostic claims were already under question through the Supreme Court's prior holdings in Bilski

Association for Molecular Pathology v. Myriad Genetics, Inc. - Wikipedia Jump to content From Wikipedia, the free encyclopedia 2013 United States Supreme Court case Association for Molecular Pathology v. Myriad Genetics, Inc. Supreme Court of the United States Argued April 15, 2013 Decided June 13, 2013 Full case name Association for Molecular Pathology, et al. v. Myriad Genetics, Inc., et al. Docket no. 12-398 Citations 569 U.S. 576 ( more ) 133 S. Ct. 2107; 186 L. Ed. 2d 124; 2013 U.S. LEXIS 4540; 81 USLW 4388; 106 U.S.P.Q.2d 1972; 13 Cal. Daily Op. Serv. 5951; 2013 Daily Journal D.A.R. 7484

Explore this link on the map →

related reading